the Sarepta chart shows that investors are disappointed that the FDA only gave Sareptas drug 901 partial approval
Also in the first 1/4 2024 Sarepta has to prove efficacy on 901 …
Let’s hope Gil Price can inform the PPMDaudience that ANP iOS a serious contender for the DMD crown.
Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK, page-25
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |